Header image

How is the management paradigm evolving for patients with B-cell ALL in 2024?

Track 2
Monday, April 29, 2024
8:00 AM - 9:30 AM
Hall 1C


The emergence of novel immune therapies has changed the standard of care for adult patients with relapsed / refractory B-cell acute lymphoblastic leukaemia (ALL) in recent years. The ‘correct’ sequencing of these agents alongside our well understood chemotherapy and stem cell transplant options presents a challenge for clinicians who treat adult patients with ALL in the modern era. In addition, novel therapeutics are actively being integrated into front line clinical trials, some of which will be available to patients in the UK by the end of 2024. Whilst the increasing availability of immunotherapies and cellular therapies is good news for our patients, it remains the case that the majority of adult patients with relapsed ALL will not be long term survivors of their disease. Our panel will discuss data from both clinical trials and real world experience to help guide clinicians in decision making when planning management pathways for their patients. Professor Fielding has been the chief investigator on numerous front line clinical trials for patients with de novo ALL within the UK. In this talk she will discuss the front line treatment of adult patients with B-cell ALL. As well as presenting data from the recently completed UKALL 14 trial, Professor Fielding will share the plans for the next national adult ALL trial, UKALL15 Dr Castleton will present data on the treatment of adult patients with relapsed / refractory B-cell ALL and will discuss the scheduling of novel agents, using examples and real world data from the UK ALL National advisory panel which she co-chairs. Dr Lannon will discuss the newly funded indications for CAR-T therapy in adults with relapsed / refractory ALL. As co-chair of the UK ALL advisory panel, she will discuss the current approvals process for patients potentially eligible for CAR-T therapy and, using a case based approach, will highlight some of the challenges experienced in managing patients through the CAR-T process.


Prof. Adele Fielding
Professor Of Haematology
University of York

First line therapy for adult patients with B-cell ALL: What next after UKALL14?

Dr. Anna Zaiga Castleton
The Christie NHS Foundation Trust

Management of adults with relapsed / refractory B-cell ALL

Dr. Michelle Lannon
Newcastle upon Tyne Hospitals NHS Foundation Trust

The role of CAR-T therapy for adult patients with relapsed / refractory B-cell ALL


Agenda Item Image
Clare Rowntree
Consultant Haematologist
University Hospital Of Wales